Personalized therapy in patients with anaplastic thyroid cancer: Targeting genetic and epigenetic alterations

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 1, 2015, Pages 35-42

  Smith, Neal ^a   Nucera, Carmelo ^a  

^a Laboratory of Human Thyroid Cancers Preclinical and Translational Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; B RAF KINASE; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TRANSCRIPTION FACTOR EZH2;

ADVANCED CANCER; ANAPLASTIC THYROID CANCER; ARTICLE; BRAF GENE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER STAGING; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE TARGETING; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PERSONALIZED MEDICINE; POINT MUTATION; PTEN GENE; TP53 GENE; TUMOR MICROENVIRONMENT; GENETIC EPIGENESIS; GENETICS; PATHOLOGY; SIGNAL TRANSDUCTION; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS;

EPIGENESIS, GENETIC; HUMANS; PRECISION MEDICINE; SIGNAL TRANSDUCTION; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS;

EID: 84920577381     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2803     Document Type: Article

References (66)

1. Smallridge RC. Approach to the patient with anaplastic thyroid carcinoma J Clin Endocrinol Metab. 2012 97, 2566-2572.
2. Nikiforov YE. Editorial: anaplastic carcinoma of the thyroid-will aurora B light a path for treatment? J Clin Endocrinol Metab. 2005; 90:1243-1245.
3. Nucera C, Eeckhoute J, Finn S, et al. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res. 2009;15:3680-3689.
4. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22:1104-1139.
5. Deshpande HA, Roman S, Sosa JA. New targeted therapies and other advances in the management of anaplastic thyroid cancer. Curr Opin Oncol. 2013;25:44-49.
6. Phay JE, Ringel MD. Metastatic mechanisms in follicular cell-derived thyroid cancer. Endocr Relat Cancer. 2013;20:R307-R319.
7. Bible KC, Foote RL, Smallridge RC. Toward improved outcomes in patients with anaplastic thyroid cancer. Oncology (Williston Park). 2012;26:398, 401, 406.
8. Liu D, Yang C, Bojdani E, Murugan AK, Xing M. Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. J Natl Cancer Inst. 2013;105:1617-1627.
9. Nikiforova MN, Kimura ET, Gandhi M, et al. B RAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-5404.
10. XingM.Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13:184-199.
11. Duquette M, Sadow PM, Lawler J, Nucera C. Thrombospondin-1 silencing down-regu lates integrin expression levels in human anaplastic thyroid cancer cells with BRAF(V600E): new insights in the host tissue adaptation and homeostasis of tumor microenvironment. Front Endocrinol (Lausanne). 2013;4:189.
12. Nucera C, Porrello A, Antonello ZA, et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA. 2010;107:10649-10654.
13. Ricarte-Filho JC, Ry der M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69:4885-4893.
14. Franco AT, Malaguarnera R, Refetoff S, et al. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci USA. 2011;108:1615-1620.
15. Shaik S, Nucera C, Inuzuka H, et al. SCF(-TRCP) suppresses an-giogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med. 2012;209: 1289-1307.
16. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer D iscov. 2013;3:520-533.
17. Nucera C. Targeting thyroid cancer microenvironment: basic research and clinical applications. Front Endocrinol (Lausanne). 2013;4:167.
18. Nehs MA, Nagarkatti S, Nucera C, Hodin RA, Parangi S. Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery. 2010;148:11 54-1162; discussion 1162.
19. Nucera C, Lawler J, Parangi S. BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res. 2011;71:2417-2422.
20. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16:17-44.
21. Smallridge RC, Copland J A. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 2010; 22:486-497.
22. Murugan AK,Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene Cancer Res. 2011 71, 4403-4411.
23. Vinagre J, Almeida A, Pópulo H, et al. Frequency ofTERTpromoter mutations in human cancers. Nat Commun. 2013;4:2185.
24. Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20:603-610.
25. Landa I, Ganly I, Chan TA, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98:E1562-E1566.
26. Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99:E754-E765.
27. Liu R, Xing M. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocr Relat Cancer. 2014;21:825-830.
28. Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32:2718-2726.
29. Liu X, Qu S, Liu R, et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 2014;99:E1130-E1136.
30. Morrison J A, Pike LA, Sams SB, et al. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Mol Cancer. 2014;13:62.
31. Bellelli R, Castellone MD, Garcia-Rostan G, et al. FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocr Relat Cancer. 2012;19:695-710.
32. Catalano MG, Fortunati N, Boccuzzi G. Epigenetics modifications and therapeutic prospects in human thyroid cancer. Front Endocrinol (Lausanne). 2012;3:40.
33. Borbone E, Troncone G, Ferraro A, et al. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. J Clin Endocrinol Metab. 2011;96:1029-1038.
34. Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer. 2008;113:2440-2447.
35. Gunda V, Cogdill AP, Bernasconi MJ, Wargo JA, Parangi S. Potential r ole of 5-Aza-2-deoxycytidine inducedMAGE-A4expression in immunotherapy for anaplastic thyroid cancer. Surgery. 2013;154: 1456-1462; discussion 1462.
36. Lin SF, Lin JD, Chou TC, Huang YY, Wong RJ. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. PLoS One. 2013;8:e77684.
37. Braun J, Hoang-Vu C, Dralle H, Hüttelmaier S. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene. 2010;29:4237-4244.
38. Zhang Z, Liu ZB, RenWM,YeXG,Zhang YY. The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. Int J Mol Med. 2012;30: 856-862.
39. Xiong Y, Zhang L, Kebebew E. MiR-20a is upregulated in anaplastic thyroid cancer and targets LIMK1. PLoS One. 2014;9:e96103.
40. Zhang Y, Yang WQ, Zhu H, et al. Regulation of autophagy by miR-30d impacts sensitivity of anaplastic thyroid carcinoma to cisplatin. Biochem Pharmacol. 2014;87:562-570.
41. Thomas L, Lai SY, Dong W, et al. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist. 2014;19:251-258.
42. Harris PJ, Bible KC. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin Investig Drugs. 2011;20:1357-1375.
43. Savvides P,Nagaiah G,Lavertu P,et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid Thyroid. 2013 23, 600-604.
44. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675-1684.
45. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714-4719.
46. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an act ive treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26:4708-4713.
47. Bible KC, Suman VJ, Menefee ME, et al. A multiinstitution al phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. 2012;97:3179-3184.
48. Guerra A, Di Crescenzo V, Garzi A, et al. Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review. BMC Surg. 2013;13(suppl 2):S44.
49. Antonello ZA, Nucera C. Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF [published online December 23, 2013]. Oncogene. doi: 10.1038/onc.2013.544.
50. Chakravarty D, Santos E, Ryder M, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011;121: 4700-4711.
51. Zhang L, Gaskins K, Yu Z, X iong Y, Merino MJ, Kebebew E. An in vivo mouse model of metastatic human thyroid cancer. Thyroid. 2014;24:695-704.
52. Nucera C, Nehs MA, Nagarkatti SS, et al. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist. 2011;16:296-309.
53. Nehs MA, Nucera C, Nagarkatti SS, et al. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology. 2012;153:985-994.
54. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467:596-599.
55. Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med. 2013;368:684-685.
56. Chan CM, Jing X, Pike LA, et al. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res. 2012;18:3580-3591.
57. Kurebayashi J, Okubo S, Yamamoto Y, et al. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother Pharmacol. 2006;58:460-470.
58. Ha HT, Lee JS, Urba S, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 2010;20:975-980.
59. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.NEngl J Med. 2013;368: 623-632.
60. Azijli K, Stelloo E, Peters GJ, VAN DEN Eertwegh AJ. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Anticancer Res. 2014; 34: 1493-1505.
61. Liu R, Liu D, Trink E, Bojdani E, Ning G, Xing M. The Akt-specific inhibitorMK2206selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pa thway. J Clin Endocrinol Metab. 2011;96:E577-E585.
62. Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer : The M. D. Anderson experience. J Clin Endocrinol Metab. 2010;95:2588-2595.
63. Swaika A, Crozier JA, Joseph RW. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther. 2014;8:775-787.
64. Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012;18:2056-2065.
65. Yap TA,Yan L,Patnaik A,et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors J Clin Oncol. 2011 29 4688-4695.
66. McDermott J, Jimeno A. Belinostat for the treatment of peripheral T-cell lymphomas. Drugs Today (Barc). 2014;50(5):337-345.